Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

IF 5.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2026-06-22 DOI:10.1007/s11864-026-01400-5

Juncong Fan, Yeqin Ni, Rong Ni, Gang Pan, You Peng, Li Zhou, Ruirui Jing, Ping Song, Dingcun Luo

{"title":"Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.","authors":"Juncong Fan, Yeqin Ni, Rong Ni, Gang Pan, You Peng, Li Zhou, Ruirui Jing, Ping Song, Dingcun Luo","doi":"10.1007/s11864-026-01400-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, restricted therapeutic options, and dismal prognosis. Conventional therapeutic modalities demonstrate limited efficacy, especially for unresectable or metastatic cases. Recent advancements in molecular profiling have revolutionized ATC management, facilitating the development of novel targeted therapies, immunotherapies, and multimodal regimens. Growing clinical evidence indicates these innovative approaches may enhance locoregional control, increase surgical candidacy in select patients, and extend overall survival. Incorporating molecular-guided therapies into multidisciplinary care is fundamentally transforming ATC management. Nevertheless, therapeutic resistance, intratumoral heterogeneity, and the paucity of large-scale prospective trials remain major obstacles. Future efforts should focus on optimizing combinatorial strategies and developing robust biomarker-driven algorithms to improve clinical outcomes in ATC.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"27 1","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-026-01400-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Opinion statement: Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, restricted therapeutic options, and dismal prognosis. Conventional therapeutic modalities demonstrate limited efficacy, especially for unresectable or metastatic cases. Recent advancements in molecular profiling have revolutionized ATC management, facilitating the development of novel targeted therapies, immunotherapies, and multimodal regimens. Growing clinical evidence indicates these innovative approaches may enhance locoregional control, increase surgical candidacy in select patients, and extend overall survival. Incorporating molecular-guided therapies into multidisciplinary care is fundamentally transforming ATC management. Nevertheless, therapeutic resistance, intratumoral heterogeneity, and the paucity of large-scale prospective trials remain major obstacles. Future efforts should focus on optimizing combinatorial strategies and developing robust biomarker-driven algorithms to improve clinical outcomes in ATC.

查看原文本刊更多论文

甲状腺间变性癌新辅助治疗的最新进展综述。

观点声明：间变性甲状腺癌（ATC）是一种高度侵袭性的恶性肿瘤，其特点是进展迅速，治疗选择有限，预后不佳。传统的治疗方式显示有限的疗效，特别是对于不可切除或转移的病例。分子谱分析的最新进展彻底改变了ATC的管理，促进了新型靶向治疗、免疫治疗和多模式治疗方案的发展。越来越多的临床证据表明，这些创新的方法可以增强局部控制，增加选择患者的手术候选资格，并延长总生存期。将分子引导疗法纳入多学科护理从根本上改变了ATC的管理。然而，治疗耐药、肿瘤内异质性和缺乏大规模前瞻性试验仍然是主要障碍。未来的努力应集中在优化组合策略和开发强大的生物标志物驱动算法，以改善ATC的临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.